The Biolocity team is excited to announce the successful license of AngioCloud, a web-based software for the treatment of brain aneurysms, by 11Ten Innovation Partners. Their technology and team are an excellent example of the success that can come from collaborations between clinicians and software engineers. This is also an opportunity where Biolocity engaged the Emory Healthcare Innovation Hub to curate the commercial opportunity for AngioCloud and source the licensing opportunity.
AngioCloud is a graduate of the Coulter program (now Biolocity), which provides funding and commercialization guidance to patient-impacting university technologies. During their time as a funded technology team, Biolocity provided financial and consulting support for prototype development and quality systems for the AngioCloud technology. “We applied with the idea that funding would be the primary determinant necessary for our success. What we learned is that the guidance, advocacy, mentorship, and regulatory resources received were every bit as critical, said Frank Tong, MD, AngioCloud co-inventor. “Our team is profoundly grateful to the Biolocity team for their guidance in translating a technical idea into a real world clinical resource that will soon benefit patients.”
“The Emory Healthcare Innovation Hub is focused on developing and commercializing technologies that make an impact on healthcare cost, quality, and access. As such, we are very excited to announce that we have licensed AngioCloud, an interventional radiology 3D imaging platform that uses computational algorithms to calculate the specifications of implantable devices”, said Will ElLaissi, Director of the Emory Healthcare Innovation Hub. “This technology helps device OEMs manage inventory and customize offerings and gives Neuro-Interventionalists the tools they need to pick the right device so that they can maximize outcomes and reduce costs.”
Biolocity is thrilled to partner our portfolio project, AngioCloud, with the Emory Healthcare Innovation Hub. “This is a great example of complimentary programs and resources working together at Emory to accelerate medical technologies to the market,” Shawna Khouri, Managing Director of Biolocity.
To learn more about AngioCloud, visit: http://www.ott.emory.edu/industry/featured/angiocloud.html
Biolocity is a philanthropic, multi-institutional program that accelerates the commercialization of medical technologies with intellectual property held at Emory University and/or Georgia Institute of Technology. Biolocity utilizes the Coulter Process: a combination of grant funding, education, and operational business expertise to de-risk academic innovations and translate them to the private sector. In the last five years, Biolocity’s 40 portfolio technologies have resulted in 20 start-ups, two industry partnerships, and three products on the market.